Andrew Morton

Andrew Morton

Auto-generated profile, based on publicly available information

Andrew Morton

Faculty of Medicine, The University of Queensland, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
PDPeter Donato
Peter Donato
MRMatthew J Roberts
Matthew J Roberts
AMAndrew Morton
Andrew Morton
SKSamuel Kyle
Samuel Kyle
GCGeoff Coughlin
Geoff Coughlin
JYJohn W. Yaxley
John W. Yaxley

22 July 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MRMatthew J Roberts
Matthew J Roberts
AMAndrew Morton
Andrew Morton
PDPeter Donato
Peter Donato
SKSamuel Kyle
Samuel Kyle
DPDavid A. Pattison
David A. Pattison
JYJohn Yaxley
John Yaxley

17 June 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
AMAndrew Morton
Andrew Morton
MWMichael Williams
Michael Williams
MPMarlon Perera
Marlon Perera
PTPatrick E. Teloken
Patrick E. Teloken
PDPeter Donato
Peter Donato
MRMatthew J Roberts
Matthew J Roberts

17 March 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
MRMatthew J Roberts
Matthew J Roberts
AMAndrew Morton
Andrew Morton
NPNathan Papa
Nathan Papa
AFAnthony Franklin
Anthony Franklin
SRSheliyan Raveenthiran
Sheliyan Raveenthiran
JYJohn W. Yaxley
John W. Yaxley
Purpose: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy. Methods: We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and 68 Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan–Meier analysis. Results: After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters. Conclusion: These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS.

11 September 2024 in BJU International
Verified
Journal Article
Open access
MRMatthew J Roberts
Matthew J Roberts
NPNathan Papa
Nathan Papa
HVHans Veerman
Hans Veerman
KBKatelijne de Bie
Katelijne de Bie
AMAndrew Morton
Andrew Morton
AVAndré Vis
André Vis
Objectives: To construct and externally calibrate a predictive model for early biochemical recurrence (BCR) after radical prostatectomy (RP) incorporating clinical and modern imaging characteristics of the primary tumour. Patients and Methods: Patients who underwent RP following multiparametric magnetic resonance imaging, prostate biopsy and prostate‐specific membrane antigen‐positron emission tomography/computed tomography (PSMA‐PET/CT), from two centres in Australia and the Netherlands. The primary outcome was biochemical recurrence‐free survival (BRFS), where BCR was defined as a rising PSA level of ≥0.2 ng/mL or initiation of postoperative treatment per clinician discretion. Proportional hazards models to predict time to event were developed in the Australian sample using relevant pre‐ and post‐surgical parameters and primary tumour maximum standardised uptake value (SUV max ) on diagnostic PSMA‐PET/CT. Calibration was assessed in an external dataset from the Netherlands with the same inclusion criteria. Results: Data from 846 patients were used to develop the models. Tumour SUV max was associated with worse predicted 3‐year BRFS for both pre‐ and post‐surgical models. SUV max change from 4 to 16 lessened the predicted 3‐year BRFS from 66% to 42% for a patient aged 65 years with typical pre‐surgical parameters (PSA level 8 ng/mL, Prostate Imaging‐Reporting and Data System score 4/5 and biopsy Gleason score ≥4 + 5). Considering post‐surgical variables, a patient with the same age and PSA level but pathological stage pT3a, RP Gleason score ≥4 + 5 and negative margins, SUV max change from 4 to 16 lessened the predicted 3‐year BRFS from 76% to 61%. Calibration on an external sample ( n = 464) showed reasonable performance; however, a tendency to overestimate survival in patients with good prognostic factors was observed. Conclusion: Tumour SUV max on diagnostic PSMA‐PET/CT has utility additional to commonly recognised variables for prediction of BRFS after RP.

1 January 2021 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
AMAndrew Morton
Andrew Morton
MWMichael Williams
Michael Williams
MPMarlon Perera
Marlon Perera
SRSachinka Ranasinghe
Sachinka Ranasinghe
PTPatrick E. Teloken
Patrick E. Teloken
MRMatthew J Roberts
Matthew J Roberts
Morton A, et al. World J Mens Health. 2021 Jan;39(1):83-89. https://doi.org/10.5534/wjmh.190166